Ignite Creation Date:
2024-05-05 @ 9:45 PM
Last Modification Date:
2024-10-26 @ 10:09 AM
Study NCT ID:
NCT00959218
Status:
COMPLETED
Last Update Posted:
2012-02-03
First Post:
2009-08-13
Brief Title:
Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis
Sponsor:
Bionorica Research GmbH
Organization:
Bionorica Research GmbH
Study Overview
Official Title:
Multi-centre Randomized Double-blind Placebo-controlled Study to Investigate the Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Patients With Multiple Sclerosis Associated With Central Neuropathic Pain
Status:
COMPLETED
Status Verified Date:
2012-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether Dronabinol is effective and safe in relieving central neuropathic pain in multiple sclerosis patients
Detailed Description:
Multiple sclerosis MS is in all probability an autoimmune disease causing severe neurological disability due to inflammation and degeneration in the central nervous system CNS MS affects over 1 million people worldwide Central neuropathic pain is associated with approximately 30 of all patients with MS MS-accompanying pain has a major impact on the patients quality of life as usual conventional analgesics are little effective The aim of this clinical study is to determine whether Dronabinol is effective and safe in relieving central neuropathic pain in multiple sclerosis patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None